<DOC>
	<DOCNO>NCT00442949</DOCNO>
	<brief_summary>Release troponin evaluate peak troponin hospital phase.Because sensitivity specificity well widespread use routine practice , rise troponin level main assessment criterion study . We plan demonstrate significantly alter distribution troponin release evaluate peak troponin patient hospitalization period ( randomization cardiologic unit discharge ) , two arm trial .</brief_summary>
	<brief_title>Angioplasty Blunt Rise Troponin Acute Coronary Syndrome ( ACS )</brief_title>
	<detailed_description>We propose evaluate optimal moment catheterization patient present acute coronary syndrome compare rapid catheterization day admission ( within 8 hour admission , average time close 3 hour , rapid strategy arm ISAR-COOL trial ) slow approach examination schedule next working day ( 8 60 hour post admission , average close 24 hour ) . Patients include present severe unstable angina define TIMI score &gt; 3 All patient must present indication catheterization receive optimal pharmacological treatment include abciximab ( ReoPro* ) undergo PCI start procedure indicate label drug ( substitution another drug class , eptifibatide tirofiban , possible catheterization laboratory accord label two drug ) . Randomization evaluate time catheterization : rapidly , soon possible follow admission ( within 8 hour admission ) versus delay approach ( 8 60 hour follow admission ) . The goal randomization determine ideal time catheterization indication catheterization , pharmacological treatment , patient care remain constant . This pragmatic study aim compare 2 different strategy management ACS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>1 . Man 18 nonpregnant woman 18 . 2 . Patient hospitalize severe acute coronary syndrome . To select patient need least 2 criterion acute coronary syndrome AND TIMI score &gt; 3 severity ACS . ACS define least two follow diagnostic criterion : ischemic symptom electrocardiographic abnormality ST segment ( depression transitory elevation least 0.1 mV ) , T wave , least two contiguous lead positive troponin ( define locally ) . Severity ACS define TIMI score &gt; 3 3. indication catheterization agree possible within follow 8 hour . 4. sign consent form 1 . Patients would require immediate catheterization ongoing refractory ischemia , major arrhythmia , hemodynamic instability eligible study . 2 . Anticoagulant therapy antivitamin K within 5 day precede randomization 3 . Thrombolytic therapy precede 24 hour 4 . Upstream treatment GPIIb/IIIa inhibitor 5 . ReoPro administer patient know sensitivity abciximab , component product murine monoclonal antibody . Because inhibition platelet aggregation increase risk bleeding , ReoPro contraindicate follow clinical situation : active internal bleeding ; history cerebrovascular accident within two year ; recent ( within two month ) intracranial intraspinal surgery trauma ; recent ( within two month ) major surgery ; intracranial neoplasm , arteriovenous malformation aneurysm ; know bleed diathesis severe uncontrolled hypertension ; preexist thrombocytopenia ; vasculitis ; hypertensive diabetic retinopathy ; severe hepatic severe renal failure . 6 . Woman nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Abciximab</keyword>
	<keyword>Troponin release</keyword>
</DOC>